PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Building on Key Milestones in Sol-gel Cannabinoid Development
Cannabinoid molecule extraction, quantification mark early successes in PreveCeutical’s drug delivery development process PreveCeutical optimistic about prototypical spray applicators in development for cannabinoid therapies Clinical trials of cannabis-based therapeutics anticipated next year PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is celebrating the achievement of several key milestones in the development of the company’s proprietary Sol-gel program for the nasal delivery of select medications, where those medications can be expected to effectively reach the nervous system in order to accomplish their purposes in treating conditions ranging from anxiety to head concussion injuries, a company officer told market reporting outlet…